The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•20 April 2026•

1 min read

FDA-Authorized Study Validates Multi-Session Psilocybin Therapy for Mental Health

Key Facts

1A Phase 1 study showed meaningful improvements in anxiety and depression following a second psilocybin session using the PEX010 drug candidate.

269% of participants fell below clinical thresholds for anxiety and depression after the second treatment.

3PEX010 is currently supplied to over 70 clinical sites globally, supporting trials for depression and PTSD.

A Phase 1 clinical study conducted under U.S. FDA authorization has demonstrated significant improvements in anxiety and depression following a second session of psilocybin therapy using the drug candidate PEX010. Data revealed that 69% of participants saw their symptoms drop below clinical thresholds after the second treatment, supporting a shift toward multi-session protocol models. Currently, PEX010 is being supplied to over 70 clinical sites globally to support ongoing trials for depression and PTSD. This clinical validation provides a boost to Red Light Holland and Filament Health as they aim to standardize psychedelic medicine. The study's success aligns with recent regulatory trends favoring expanded research into psychedelic-assisted therapies. While the results are bullish for the biotech sector, investors remain cautious as the drug candidate progresses through early-stage clinical milestones. This development underscores the potential for repeatable, protocol-driven treatments to improve long-term patient outcomes.